Home Behandelprotocollen LCH Richtlijnen en literatuur

Richtlijnen

 
Er is op dit moment geen behandelrichtlijn voor LCH. 

Literatuur

  1. Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood 2015; 126(1): 26-35. doi: 10.1182/blood-2014-12-569301
  2. Allen CE, Merad M, McClain KL. Langerhans cell histiocytosis. The New England journal of medicine 2018; 379(9): 856-868. doi: 10.1056/NEJMra1607548
  3. Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127(22): 2672-2681. doi: 10.1182/blood-2016-01-690636
  4. Frater JL. The histiocytoses: as easy as ABC (or LCMRH). Blood 2016; 127(22): 2655-2656. doi: 10.1182/blood-2016-03-706267
  5. Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 2014; 124(4): 483-492. e-pub ahead of print 2014/05/23; doi: 10.1182/blood-2014-03-561381
  6. Hervier B, Haroche J, Arnaud L, Charlotte F, Donadieu J, Neel A et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 2014; 124(7): 1119-1126. e-pub ahead of print 2014/06/05; doi: 10.1182/blood-2013-12-543793
  7. Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood 2020; 135(16): 1319-1331. e-pub ahead of print 2020/02/28; doi: 10.1182/blood.2019000934
  8. McClain KL, Picarsic J, Chakraborty R, Zinn D, Lin H, Abhyankar H et al. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer 2018; 124(12): 2607-2620. doi: 10.1002/cncr.31348 
  9. Ma J, Laird JH, Chau KW, Chelius MR, Lok BH, Yahalom J. Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies. Cancer medicine 2019; 8(1): 58-66. e-pub ahead of print 2019/01/01; doi: 10.1002/cam4.1844
  10. Goyal G, Heaney ML, Collin M, Cohen Aubart F, Vaglio A, Durham BH et al. Erdheim-Chester disease: Consensus recommendations for the evaluation, diagnosis, and treatment in the molecular era. Blood 2020. e-pub ahead of print 2020/03/19; doi: 10.1182/blood.2019003507
  11. Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C, Fichter J et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis 2013; 8: 72. doi: 10.1186/1750-1172-8-72 
  12. Yeh EA, Greenberg J, Abla O, Longoni G, Diamond E, Hermiston M et al. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatric blood & cancer 2018; 65(1). e-pub ahead of print 2017/09/26; doi: 10.1002/pbc.26784 
  13. Gadner H, Grois N, Potschger U, Minkov M, Arico M, Braier J et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008; 111(5): 2556-2562. e-pub ahead of print 2007/12/20; doi: 10.1182/blood-2007-08-106211 
  14. Tazi A, Lorillon G, Haroche J, Neel A, Dominique S, Aouba A et al. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Orphanet J Rare Dis 2017; 12(1): 95. e-pub ahead of print 2017/05/24; doi: 10.1186/s13023-017-0651-z 
  15. McClain KL. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert opinion on pharmacotherapy 2005; 6(14): 2435-2441. e-pub ahead of print 2005/11/02; doi: 10.1517/14656566.6.14.2435

Ga terug naar de LCH homepage of lees meer over LCH: Ga terug naar de algemene homepage Behandelprotocollen.